Rational use of tocilizumab in COVID-19

Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31.

Authors

Siddharth Jain¹, Shefali Khanna Sharma²

Affiliations

¹ Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
² Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India sharmashefali@hotmail.com.

PMID: 32737106
DOI: 10.1136/annrheumdis-2020-218519

No abstract available

Keywords: antirheumatic agents; biological therapy; communicable diseases, imported; cytokines; inflammation.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab